Sleep Patterns Among Patients with Chronic Fatigue: a Polysomnography‐Based Study
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Restless Legs Syndrome in Patients with Epilepsy Under Levetiracetam Monotherapy
Original Article / Özgün Makale DODO I: 10.4274/ I: 10.4274/jtsm.xxxjtsm.69188 Journal of Turkish Sleep Medicine 2018;5:12-6 Restless Legs Syndrome in Patients with Epilepsy Under Levetiracetam Monotherapy Levetirasetam Monoterapisi Altında Epilepsi Hastalarında Huzursuz Bacak Sendromu Gülnihal Kutlu, Fatma Genç*, Yasemin Ünal, Dilek Aslan Öztürk, Abidin Erdal*, Yasemin Biçer Gömceli* Muğla Sıtkı Koçman University Faculty of Medicine, Department of Neurology, Muğla, Turkey *University of Health Sciences, Antalya Training and Research Hospital, Clinic of Neurology, Antalya, Turkey Abstract Öz Objective: Restless Legs syndrome (RLS) is a frequent neurological Amaç: Huzursuz Bacak sendromu (HBS) sık görülen bir nörolojik disease. Levetiracetam (LEV) is an effective and broad-spectrum hastalıktır. Levetirasetam (LEV) etkili ve geniş spektrumlu bir antiepileptik anticonvulsant drug. The aim of this study is to investigate the frequency ilaçtır. Bu çalışmanın amacı epilepsi tanısı ile LEV monoterapisi alan of RLS in patients diagnosed with epilepsy who took LEV monotherapy. hastalarda HBS sıklığını araştırmaktır. Materials and Methods: Two neurologists were reviewed the files of Gereç ve Yöntem: Epilepsi polikliniğinde takip edilen 1680 hastanın 1680 patients, who were followed in epilepsy outpatient clinic. One dosyası iki nörolog tarafından gözden geçirildi. En az 6 aydır LEV hundred seven patients under LEV monotherapy for at least six months monoterapisi alan 107 hasta ve 120 sağlıklı kontrol çalışmaya alındı. and 120 healthy controls were included in the study. The criteria for the International Restless Legs Syndrome Study Group were taken into HBS değerlendirmesi için Uluslararası Huzursuz Bacak Sendromu Çalışma consideration for the assessment of RLS. Grubu’nun kriterleri göz önüne alındı. Results: The mean age of patient group was 38.26±17.39 years, while Bulgular: Sağlıklı kontrollerin ortalama yaşı 39,17±16,12 yıl iken, the mean age of healthy controls was 39.17±16.12 years. -
Fatigue and Parkinson's Disease
Fatigue and Parkinson’s Disease Gordon Campbell MSN FNP PADRECC Portland VAMC, October 24, 2014 Sponsored by the NW PADRECC - Parkinson's Disease Research, Education & Clinical Center Portland VA Medical Center www.parkinsons.va.gov/Northwest Outline • What is fatigue? • How differs from sleepiness, depression • How do doctors measure it? • Why is fatigue such a problem in PD? • How if fatigue in PD different? • How will exercise and nutrition help? • Will medications work? What is Fatigue? • One of most common symptoms in medicine. • Fatigue is the desire to rest. No energy. • Chronic fatigue: “overwhelming and sustained exhaustion and decreased capacity to physical or mental work, not relieved by rest • Acute (days) or chronic (months, years) • May be incapacitating • Cannot be checked with doctor’s exam – Not like tremor, stiffness 1 Fatigue: What Is It? • Not sleepiness (cannot stay awake) • Not depression (blue, hopeless, cranky) • Rather is sustained exhaustion and decreased capacity for physical and mental work that is not relieved by rest – Get up tired after a night's sleep, always tired. • Also, a subjective lack of physical and/or mental energy that interferes with usual and desired activities Fatigue: A Big Problem • 10 million physician office visits/year in USA. • Usual cause for this fatigue in general doctor’s office = depression. • Different in Parkinson’s disease, various other medical illnesses. 2 Many Illnesses and Drugs Cause Fatigue • Medical diseases – Diabetes – Thyroid disease (too low or too high) – Emphysema, heart failure – Rheumatologic diseases – Cancer or radiation therapy – Anemia • Drugs – Beta blockers, antihistamines, pain killers, alcohol • Other neurological diseases – Strokes – Post polio syndrome – Narcolepsy, obstructive sleep apnea – Old closed head injuries – Multiple sclerosis 5 Dimensions of Fatigue • General fatigue • Physical fatigue • Mental fatigue • Reduced motivation • Reduced activity Depression correlates with all 5 dimensions. -
Brain Imaging Reveals Clues About Chronic Fatigue Syndrome 23 May 2014
Brain imaging reveals clues about chronic fatigue syndrome 23 May 2014 The results are scheduled for publication in the journal PLOS One. "We chose the basal ganglia because they are primary targets of inflammation in the brain," says lead author Andrew Miller, MD. "Results from a number of previous studies suggest that increased inflammation may be a contributing factor to fatigue in CFS patients, and may even be the cause in some patients." Miller is William P. Timmie professor of psychiatry and behavioral sciences at Emory University School of Medicine. The study was a collaboration among researchers at Emory University School of Medicine, the CDC's Chronic Viral Diseases Branch, and the University of Modena and Reggio Credit: Vera Kratochvil/public domain Emilia in Italy. The study was funded by the CDC. The basal ganglia are structures deep within the brain, thought to be responsible for control of A brain imaging study shows that patients with movements and responses to rewards as well as chronic fatigue syndrome may have reduced cognitive functions. Several neurological disorders responses, compared with healthy controls, in a involve dysfunction of the basal ganglia, including region of the brain connected with fatigue. The Parkinson's disease and Huntington's disease, for findings suggest that chronic fatigue syndrome is example. associated with changes in the brain involving brain circuits that regulate motor activity and In previous published studies by Emory motivation. researchers, people taking interferon alpha as a treatment for hepatitis C, which can induce severe Compared with healthy controls, patients with fatigue, also show reduced activity in the basal chronic fatigue syndrome had less activation of the ganglia. -
Fatigue After Stroke
SPECIAL REPORT Fatigue after stroke PJ Tyrrell Fatigue is a common symptom after stroke. It is not invariably related to stroke severity & DG Smithard† and can occur in the absence of depression. It is one of the most troublesome symptoms for †Author for correspondence many patients and yet nothing is known of its causation. There are no specific treatments. William Harvey Hospital, Richard Steven’s Ward, This article assesses the available literature in the context of what is known about fatigue Ashford, Kent, in other disorders. Post-stroke fatigue may be a manifestation of sickness behavior, TN24 0LZ, UK mediated through the central effects of the cytokine interleukin-1, perhaps via effects on Tel.: +44 123 361 6214 Fax: +44 123 361 6662 glutamate neurotransmission. Possible therapeutic strategies are discussed which might be [email protected] a logical basis from which to plan randomized control trials. Following stroke, approximately a third of common and disabling symptom of Parkinson’s patients die, a third recover and a third remain disease [7,8] and of systemic lupus [9]. More than significantly disabled. Even those who recover 90% of patients with poliomyelitis develop a physically may be left with significant emotional delayed syndrome of post-myelitis fatigue [10]. and psychologic dysfunction – including anxi- Fatigue is the most prevalent symptom of ety, readjustment reactions and depression. One patients with cancer who receive radiation, cyto- common but often overlooked symptom is toxic or other therapies [11], and it may persist fatigue. This may occur soon or late after stroke, for years after the cessation of treatment [12]. -
Parasite Linked to Dementia, Cognitive Impairment
May 2008 • www.clinicalneurologynews.com News 5 Parasite Linked to Dementia, Cognitive Impairment ARTICLES BY AMY ROTHMAN that 5 (12.5%) of treatment-naive patients but other lesions also can be related, and are SCHONFELD diagnosed with neurocysticercosis met located anywhere in the brain. Contributing Writer DSM IV criteria for dementia, significant- Humans become infected with neuro- ly more than the normal control group (P cysticercosis through consumption of food C HICAGO — Untreated central nervous less than .05). Major memory impairment or water contaminated with the feces of a system infection with the parasitic neuro- was found in 23 (57.5%). On a battery of NDRADE Taenia solium tapeworm carrier. The adult cysticercosis may present as cognitive im- cognitive tests that evaluated memory, at- A tapeworms are found only in the intestine pairment ranging from mild deficit to tention, praxis, and executive function, all of humans. Once the tapeworm lays its IAMPI DE full-blown dementia. those with neurocysticercosis demon- C eggs, the larvae may invade tissue and Neurocysticercosis is the most common strated one or more cognitive deficits, a through the bloodstream infect skeletal parasitic infection of the CNS. Even physi- significantly higher rate than observed for ANIEL muscles, the eyes, brain, and spinal cord. A . D R cians may be unaware of infection’s ad- the normal controls (P less than .05). In- D person can be infested by T. solium and be verse effects on cognition, according to Dr. terestingly, when compared with patients a carrier, but not develop cysticercosis. Daniel Ciampi de Andrade. with cryptogenic epilepsy, neurocysticer- Dr. -
Frequent Difficulties in the Treatment of Restless Legs Syndrome – Case Report and Literature Review
Psychiatr. Pol. 2015; 49(5): 921–930 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/PP/35395 Frequent difficulties in the treatment of restless legs syndrome – case report and literature review Dominika Narowska 1, Milena Bożek 2, Katarzyna Krysiak 3, Jakub Antczak3, Justyna Holka-Pokorska1, Wojciech Jernajczyk3, Adam Wichniak1 1 Third Department of Psychiatry, Institute of Psychiatry and Neurology in Warsaw 2 First Department of Psychiatry, Institute of Psychiatry and Neurology in Warsaw 3 Department of Clinical Neurophysiology, Sleep Disorders Centre, Institute of Psychiatry and Neurology in Warsaw Summary Restless legs syndrome (RLS) is one of the most common sleep disorders. The purpose of this paper is a case description of the patient suffering from RLS, concurrent with numer- ous clinical problems. In our patient, during long-term therapy with a dopamine agonist (ropinirole), the phenomenon of the augmentation, defined as an increase in the severity of the RLS symptoms, was observed. The quality of life of the patient was significantly dete- riorated. Due to the augmentation of RLS symptoms the dopaminergic drug was gradually withdrawn, and the gabapentin as a second-line drug for the treatment of RLS was introduced. Because of the large increase of both insomnia and RLS symptoms during the reduction of ropinirole dose, clonazepam was temporarily introduced. In addition, in the neurological as- sessment of the distal parts of the lower limb sensory disturbances of vibration were found. The neurographic study confirmed axonal neuropathy of the sural nerves, which explained an incomplete response to dopaminergic medications. -
ME/CFS) Key Facts
KEY FACTS FEBRUARY 2015 For more information visit www.iom.edu/MECFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Key Facts What is the prevalence of ME/CFS? • ME/CFS affects 836,000 to 2.5 million Americans. • An estimated 84 to 91 percent of people with ME/CFS have not yet been diagnosed, meaning the true prevalence of ME/CFS is unknown. • ME/CFS affects women more often than men. Most patients currently diagnosed with ME/CFS are Caucasian, but some studies suggest that ME/CFS is more common in minority groups. • The average age of onset is 33, although ME/CFS has been reported in patients younger than age 10 and older than age 70. What are the symptoms and other effects of ME/CFS? • There are five main symptoms of ME/CFS: 1. Reduction or impairment in ability to carry out normal daily activities, accompanied by pro- found fatigue; 2. Post-exertional malaise (worsening of symptoms after physical, cognitive, or emotional effort); 3. Unrefreshing sleep; 4. Cognitive impairment; and 5. Orthostatic intolerance (symptoms that worsen when a person stands upright and improve when the person lies back down). • Other common manifestations of ME/CFS include pain, failure to recover from a prior infection, and abnormal immune function. • At least one-quarter of ME/CFS patients are bed- or house-bound at some point in their illness. • Symptoms can persist for years, and most patients never regain their pre-disease level of health or functioning. • ME/CFS patients experience loss of productivity and high medical costs that contribute to a total economic burden of $17 to $24 billion annually. -
HEADACHES and ME/CFS INTRODUCTION Headaches Are Often Reported by People with ME/CFS
MANAGEMENT FILE the ME association by DR CHARLES SHEPHERD, our medical adviser This leaflet is based on an article which first appeared in the ME Association’s quarterly ME Essential magazine. MEA membership costs £18 a year for people living in the UK/BFPO. For contact details, see foot of this page. February 2020 HEADACHES AND ME/CFS INTRODUCTION Headaches are often reported by people with ME/CFS. They also form part of the symptom list for most diagnostic criteria for ME/CFS. But headaches can obviously have other causes – physical and psychological – as well. WHAT CAUSES HEADACHES? Doctors classify headaches as being sides of the head – as if a rubber band arteries in the head and neck. primary where there is no obvious link has been stretched around it. Common Temporal arteritis is a medical to an underlying medical problem, or causes include stress, depression, lack emergency that requires urgent treat- secondary where there is a clear link. of proper sleep, skipping meals, not ment with high-dose steroids. drinking enough fluid and alcohol. Primary headaches include: Headaches in women can be caused Secondary headaches are caused by Cluster headaches by hormonal problems – including an existing medical problem. Some of An excruciatingly painful headache taking the contraceptive pill, going these are serious, which is why you must that causes intense pain around one through the menopause, pregnancy, see your doctor if you have severe or eye. Cluster headaches are fairly rare and as part of period pain. persistent headaches. and tend to occur in clusters for a It’s also worth noting that a headache month or two, sometimes around the Common causes, which are normally is the most common symptom of same time each year. -
Chronic Fatigue Syndrome (CFS) Disease Fact Sheet Series
WISCONSIN DIVISION OF PUBLIC HEALTH Department of Health Services Chronic Fatigue Syndrome (CFS) Disease Fact Sheet Series What is chronic fatigue syndrome? Chronic fatigue syndrome (CFS) is a recently defined illness consisting of a complex of related symptoms. The most characteristic symptom is debilitating fatigue that persists for several months. What are the other symptoms of CFS? In addition to profound fatigue, some patients with CFS may complain of sore throat, slight fever, lymph node tenderness, headache, muscle and joint pain (without swelling), muscle weakness, sensitivity to light, sleep disturbances, depression, and difficulty in concentrating. Although the symptoms tend to wax and wane, the illness is generally not progressive. For most people, symptoms plateau early in the course of the illness and recur with varying degrees of severity for at least six months and sometimes for several years. What causes CFS? The cause of CFS is not yet known. Early evidence suggested that CFS might be associated with the body's response to an infection with certain viruses, however subsequent research has not shown an association between an infection with any known human pathogen and CFS. Other possible factors that have been suspected of playing a role in CFS include a dysfunction in the immune system, stress, genetic predisposition, and a patient’s psychological state. Is CFS contagious? Because the cause of CFS remains unknown, it is impossible to answer this question with certainty. However, there is no convincing evidence that the illness can be transmitted from person to person. In fact, there is no indication at this time that CFS is caused by any single recognized infectious disease agent. -
The Management of Restless Legs Syndrome in Adults in Primary Care
The Management of Restless Legs Syndrome in Adults in Primary Care Victoria Birchall /Susan McKernan Midlands and Lancashire CSU December 2015 (Review date November 2018) VERSION CONTROL Version Number Date Amendments made 1.0 December Version 1. Approved 2015 Contents VERSION CONTROL ........................................................................................................... 2 1. INTRODUCTION ........................................................................................................... 3 2. PURPOSE AND SUMMARY ......................................................................................... 3 3. SCOPE .......................................................................................................................... 3 4. GUIDANCE .................................................................................................................... 3 5. REFERENCES .............................................................................................................. 8 6. ACKNOWLEDGEMENTS .............................................................................................. 8 Please access documents via the LMMG website to ensure the correct version is in use. 1. INTRODUCTION Restless Legs Syndrome (RLS), also known as Willis-Ekborn disease, is a common sensory motor neurological disorder which causes a characteristic, overwhelming and irresistible urge to move the limbs, usually the legs but can also additionally affect the arms – in addition to uncomfortable, abnormal sensations which -
Migraine Headaches in Chronic Fatigue Syndrome (CFS)
Ravindran et al. BMC Neurology 2011, 11:30 http://www.biomedcentral.com/1471-2377/11/30 RESEARCHARTICLE Open Access Migraine headaches in Chronic Fatigue Syndrome (CFS): Comparison of two prospective cross- sectional studies Murugan K Ravindran, Yin Zheng, Christian Timbol, Samantha J Merck, James N Baraniuk* Abstract Background: Headaches are more frequent in Chronic Fatigue Syndrome (CFS) than healthy control (HC) subjects. The 2004 International Headache Society (IHS) criteria were used to define CFS headache phenotypes. Methods: Subjects in Cohort 1 (HC = 368; CFS = 203) completed questionnaires about many diverse symptoms by giving nominal (yes/no) answers. Cohort 2 (HC = 21; CFS = 67) had more focused evaluations. They scored symptom severities on 0 to 4 anchored ordinal scales, and had structured headache evaluations. All subjects had history and physical examinations; assessments for exclusion criteria; questionnaires about CFS related symptoms (0 to 4 scale), Multidimensional Fatigue Inventory (MFI) and Medical Outcome Survey Short Form 36 (MOS SF-36). Results: Demographics, trends for the number of diffuse “functional” symptoms present, and severity of CFS case designation criteria symptoms were equivalent between CFS subjects in Cohorts 1 and 2. HC had significantly fewer symptoms, lower MFI and higher SF-36 domain scores than CFS in both cohorts. Migraine headaches were found in 84%, and tension-type headaches in 81% of Cohort 2 CFS. This compared to 5% and 45%, respectively, in HC. The CFS group had migraine without aura (60%; MO; CFS+MO), with aura (24%; CFS+MA), tension headaches only (12%), or no headaches (4%). Co-morbid tension and migraine headaches were found in 67% of CFS. -
The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: a Report from the Socioeconomics Working Group of Th
medicina Opinion The Role of Prevention in Reducing the Economic Impact of ME/CFS in Europe: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE) Derek F. H. Pheby 1,* , Diana Araja 2 , Uldis Berkis 3, Elenka Brenna 4 , John Cullinan 5 , Jean-Dominique de Korwin 6,7 , Lara Gitto 8 , Dyfrig A. Hughes 9 , Rachael M. Hunter 10 , Dominic Trepel 11 and Xia Wang-Steverding 12 1 Society and Health, Buckinghamshire New University, High Wycombe HP11 2JZ, UK 2 Department of Dosage Form Technology, Faculty of Pharmacy, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia; [email protected] 3 Institute of Microbiology and Virology, Riga Stradins University, Dzirciema Street 16, LV-1007 Riga, Latvia; [email protected] 4 Department of Economics and Finance, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 1, 20123 Milan, Italy; [email protected] 5 School of Business & Economics, National University of Ireland Galway, University Road, H91 TK33 Galway, Ireland; [email protected] 6 Internal Medicine Department, University of Lorraine, 34, Cours Léopold CS 25233, F-54052 Nancy, France; Citation: Pheby, D.F.H.; Araja, D.; [email protected] 7 Berkis, U.; Brenna, E.; Cullinan, J.; de University Hospital of Nancy, Rue du Morvan, 54511 Vandoeuvre-Les-Nancy, France 8 Department of Economics, University of Messina, Piazza Pugliatti 1, 98122 Messina, Italy; [email protected] Korwin, J.-D.; Gitto, L.; Hughes, D.A.; 9 Centre for Health Economics & Medicines Evaluation, Bangor University, Bangor LL57 2PZ, UK; Hunter, R.M.; Trepel, D.; et al.